Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients
Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research for DMD
Precision BioSciences, a clinical-stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and […]
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]
NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London
NeoPhore, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic […]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
Acadia Pharmaceuticals today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett […]
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced […]
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx announced today that they have entered into a collaboration agreement to jointly […]
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia
Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more